Literature DB >> 15795301

Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease.

Colm Cunningham1, David C Wilcockson, Delphine Boche, V Hugh Perry.   

Abstract

Chronic neurodegenerative diseases such as prion disease and Alzheimer's disease (AD) are reported to be associated with microglial activation and increased brain and serum cytokines and acute-phase proteins (APPs). Unlike AD, prion disease is also associated with a peripheral component in that the presumed causative agent, PrPSc, also accumulates in the spleen and other lymphoreticular organs. It is unclear whether the reported systemic acute-phase response represents a systemic inflammatory response to prion disease or merely reflects central nervous system (CNS) inflammation. For this study, we investigated whether intracerebrally initiated prion disease (ME7 model) provokes splenic, hepatic, or brain inflammatory and acute-phase responses. We detected no significant elevation of proinflammatory cytokines or activation of macrophages in the spleens of these animals, despite clear PrPSc deposition. Similarly, at 19 weeks we detected no significant elevation of transcripts for the APPs serum amyloid A, complement C3, pentraxin 3, and alpha2-antiplasmin in the liver, despite CNS neurodegeneration and splenic PrPSc deposition at this time. However, despite the low CNS expression levels of proinflammatory cytokines, there was robust expression of these APPs in degenerating brains. These findings suggest that PrPSc is not a stimulus for splenic macrophages and that neither peripheral PrPSc deposition nor CNS neurodegeneration is sufficient to produce a systemic acute-phase response. We also propose that serum cytokine and APP measurements are not useful during preclinical disease. Possible consequences of the clear chronic elevation of APPs in the CNS are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795301      PMCID: PMC1069550          DOI: 10.1128/JVI.79.8.5174-5184.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Fibrillar prion peptide (106-126) and scrapie prion protein hamper phagocytosis in microglia.

Authors:  Jaroslava Ciesielski-Treska; Nancy J Grant; Gabrielle Ulrich; Matthias Corrotte; Yannick Bailly; Anne-Marie Haeberle; Sylvette Chasserot-Golaz; Marie-France Bader
Journal:  Glia       Date:  2004-04-15       Impact factor: 7.452

2.  Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain.

Authors:  V H Perry; D A Hume; S Gordon
Journal:  Neuroscience       Date:  1985-06       Impact factor: 3.590

3.  CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury.

Authors:  Sandra J Campbell; Paula M Hughes; John P Iredale; David C Wilcockson; Sara Waters; Fabian Docagne; V Hugh Perry; Daniel C Anthony
Journal:  FASEB J       Date:  2003-04-22       Impact factor: 5.191

4.  Biochemical and functional characterization of the interaction between pentraxin 3 and C1q.

Authors:  Alma J Nauta; Barbara Bottazzi; Alberto Mantovani; Giovanni Salvatori; Uday Kishore; Wilhelm J Schwaeble; Alexandre R Gingras; Sotiria Tzima; Fernando Vivanco; Jesús Egido; Odette Tijsma; Erik C Hack; Mohamed R Daha; Anja Roos
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

5.  Inducible cytokine gene expression in the brain in the ME7/CV mouse model of scrapie is highly restricted, is at a strikingly low level relative to the degree of gliosis and occurs only late in disease.

Authors:  Alan R Brown; Jeanette Webb; Selma Rebus; Robert Walker; Alun Williams; John K Fazakerley
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

6.  Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease.

Authors:  C Cunningham; R Deacon; H Wells; D Boche; S Waters; C Picanco Diniz; H Scott; J N P Rawlins; V H Perry
Journal:  Eur J Neurosci       Date:  2003-05       Impact factor: 3.386

7.  Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha.

Authors:  G Ramadori; J Van Damme; H Rieder; K H Meyer zum Büschenfelde
Journal:  Eur J Immunol       Date:  1988-08       Impact factor: 5.532

8.  CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes.

Authors:  G J Wolbink; M C Brouwer; S Buysmann; I J ten Berge; C E Hack
Journal:  J Immunol       Date:  1996-07-01       Impact factor: 5.422

9.  Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins.

Authors:  R F Mortensen; J Shapiro; B F Lin; S Douches; R Neta
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

10.  CD36 mediates the innate host response to beta-amyloid.

Authors:  Joseph B El Khoury; Kathryn J Moore; Terry K Means; Josephine Leung; Kinya Terada; Michelle Toft; Mason W Freeman; Andrew D Luster
Journal:  J Exp Med       Date:  2003-06-09       Impact factor: 14.307

View more
  25 in total

1.  Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge.

Authors:  Diana M Norden; Paige J Trojanowski; Emmanuel Villanueva; Elisa Navarro; Jonathan P Godbout
Journal:  Glia       Date:  2015-10-15       Impact factor: 7.452

2.  IL-1 family members as candidate genes modulating scrapie susceptibility in sheep: localization, partial characterization, and expression.

Authors:  Ane Marcos-Carcavilla; Jorge H Calvo; Carmen González; Katayoun Moazami-Goudarzi; Pascal Laurent; Maud Bertaud; Hélène Hayes; Anne E Beattie; Carmen Serrano; Jaber Lyahyai; Inmaculada Martín-Burriel; Estefânia Alves; Pilar Zaragoza; Juan J Badiola; Magdalena Serrano
Journal:  Mamm Genome       Date:  2007-01-22       Impact factor: 2.957

Review 3.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction.

Authors:  James A Carroll; James F Striebel; Brent Race; Katie Phillips; Bruce Chesebro
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

5.  β-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat.

Authors:  Eric S Wohleb; Mark L Hanke; Angela W Corona; Nicole D Powell; La'Tonia M Stiner; Michael T Bailey; Randy J Nelson; Jonathan P Godbout; John F Sheridan
Journal:  J Neurosci       Date:  2011-04-27       Impact factor: 6.167

6.  Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease.

Authors:  Colm Cunningham; Suzanne Campion; Katie Lunnon; Carol L Murray; Jack F C Woods; Robert M J Deacon; J Nicholas P Rawlins; V Hugh Perry
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 7.  The role of microglia in synaptic stripping and synaptic degeneration: a revised perspective.

Authors:  V Hugh Perry; Vincent O'Connor
Journal:  ASN Neuro       Date:  2010-10-14       Impact factor: 4.146

8.  Presence of an acute phase response in sheep with clinical classical scrapie.

Authors:  Siv Meling; Kjetil Bårdsen; Martha J Ulvund
Journal:  BMC Vet Res       Date:  2012-07-17       Impact factor: 2.741

9.  Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Authors:  Orla Cunningham; Suzanne Campion; V Hugh Perry; Carol Murray; Nicolai Sidenius; Fabian Docagne; Colm Cunningham
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

Review 10.  Prion disease and the innate immune system.

Authors:  Barry M Bradford; Neil A Mabbott
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.